Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Provided By GlobeNewswire
Last update: Oct 15, 2024
Completes Transition to Immune-Mediated Disease Focused Company
Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025
Read more at globenewswire.com
